ScholarLens Back to search
2002•Chinese Journal of Clinkal Oncology and RehabilitationRequires access

Clinical study on BVMAP regimen in the treatment of refractory non-Hodgkin′s lymphoma

HE Ze-ming

Open publisher page 0 citations

Abstract

Objective To observe the effect of BVMAP regimen in treatment of refractory non-Hodgkin′s lymphoma.Methods BVMAP regimen:BLM 10mg/m 2,d1,3,5;VDS 3mg/m 2,d1,8;MTX 120mg/m 2,d1,8;Ara-C 60mg/m 2,d1～5;PDN 30mg/m 2,d1～14.Cycles repeated for 28 days.All the patients received over two cycles of chemotherapy.Results In all 30 patients,60% of response rate were achieved with 5 cases CR,13 cases PR,10 cases NC,2 cases PD.Main toxicities were neutropenia and thrombocytopenia with occurrence rate of 86.7% and 60.0% respectively.Conclusion BVMAP regimen in the treatment of refractory non-Hodgkin′s lymphoma is an active regimen with relatively low toxicity and well tolerance.

About this research paper

What this paper is about

Objective To observe the effect of BVMAP regimen in treatment of refractory non-Hodgkin′s lymphoma.Methods BVMAP regimen:BLM 10mg/m 2,d1,3,5;VDS 3mg/m 2,d1,8;MTX 120mg/m 2,d1,8;Ara-C 60mg/m 2,d1～5;PDN 30mg/m 2,d1～14.Cycles repeated for 28 days.All the patients received over two cycles of chemotherapy.Results In all 30 patients,60% of response rate were achieved with 5 cases CR,13 cases PR,10 cases NC,2 cases PD.Main toxicities were neutropenia and thrombocytopenia with occurrence rate of 86.7% and 60.0% respectively.Conclusion BVMAP regimen in the treatment of refractory non-Hodgkin′s lymphoma is an active regimen with relatively low toxicity and well tolerance.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To observe the effect of BVMAP regimen in treatment of refractory non-Hodgkin′s lymphoma.Methods BVMAP regimen:BLM 10mg/m 2,d1,3,5;VDS 3mg/m 2,d1,8;MTX 120mg/m 2,d1,8;Ara-C 60mg/m 2,d1～5;PDN 30mg/m 2,d1～14.Cycles repeated for 28 days.All the patients received over two cycles of chemotherapy.Results In all 30 patients,60% of response rate were achieved with 5 cases CR,13 cases PR,10 cases NC,2 cases PD.Main toxicities were neutropenia and thrombocytopenia with occurrence rate of 86.7% and 60.0% respectively.Conclusion BVMAP regimen in the treatment of refractory non-Hodgkin′s lymphoma is an active regimen with relatively low toxicity and well tolerance.

Key concepts: Medicine, Regimen, Refractory (planetary science), Neutropenia, Internal medicine, Gastroenterology, Lymphoma, Chemotherapy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical study on BVMAP regimen in the treatment of refractory non-Hodgkin′s lymphoma — Research Paper | ScholarLens